Amarin Corp Plc (AMRN)

[HDGabor]

Amarin BD for AdCom: "Total LDL-P concentration decreased 7.7 percentage points with Vascepa 4 g/day versus placebo (p=0.0017) and decreased 7.5 percentage points for 2 g/day Vascepa versus placebo (p=0.0013), which was driven by decreases in small LDL-P concentrations (–13.5 percentage points for Vascepa 4g/day (p<0.0001) and –14.7 percentage points for Vascepa 2 g/day (p<0.0001), both compared to placebo). LDL-P size increased with Vascepa 4 g/day (+0.5, p=0.0031) and 2 g/day (+0.5, p=0.0007) compared to placebo."

and now:

"We now have real-world evidence from a large-scale study of commercially insured patients to support the use of LDL-P measurement as an LDL management tool, based on the more favorable clinical outcomes we observed in patients achieving target LDL-P levels, compared to LDL-C targets."

Study Published in Atherosclerosis Provides First Large-Scale, Real-World Evidence of Link Between Low LDL Particle Levels and Reduced Risk of Cardiovascular Disease